COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform

被引:37
作者
Chattu, Vijay Kumar [1 ,2 ,3 ]
Singh, Bawa [4 ]
Kaur, Jaspal [5 ]
Jakovljevic, Mihajlo [6 ,7 ,8 ]
机构
[1] Univ Toronto, Fac Med, Dept Med, Div Occupat Med, Toronto, ON, Canada
[2] Saveetha Univ, Saveetha Med Coll, Saveetha Inst Med & Tech Sci, Dept Publ Hlth, Chennai 600077, Tamil Nadu, India
[3] Univ West Indies, Inst Int Relat, St Augustine, Trinidad Tobago
[4] Cent Univ Punjab, Sch Int Studies, Dept South & Cent Asian Studies, Bathinda 151401, India
[5] Guru Nanak Dev Univ, Dept Law, Reg Campus, Jalandhar 144007, Punjab, India
[6] Univ Kragujevac, Fac Med Sci, Dept Global Hlth Econ & Policy, Kragujevac 34000, Serbia
[7] Hosei Univ, Inst Comparat Econ, Tokyo 1940298, Japan
[8] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Dept Publ Hlth & Healthcare, Moscow, Russia
关键词
EXPENDITURE;
D O I
10.1155/2021/6658070
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In light of the devastation caused by COVID-19, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and vaccine research and development (R&D) have been occupying a prominent position in the field of global health diplomacy (GHD). Most countries, international organizations, and charitable organizations have been engaged in the R&D of COVID-19 vaccines to ensure timely affordability and accessibility to all countries. Concomitantly, the World Trade Organization (WTO) provides some provisions and enforcements regarding copyrights, patents, trademarks, geographical indications, and industrial designs. Given these safeguards, it is considered that intellectual property rights (IPRs) have become major barriers to the affordability and accessibility of vaccines/medicines/technology, particularly to the developing/least developed countries. Realizing the gravity of the pandemic impact, as well as its huge population and size, India has elevated this issue in its global health diplomacy by submitting a joint proposal with South Africa to the World Trade Organization (WTO) for a temporary waiver of IPRs to ensure timely affordability and accessibility of COVID-19 medical products to all countries. However, the issue of the temporary waive off had become a geopolitical issue. Countries that used to claim per se as strong advocates of human rights, egalitarianism, and healthy democracy have opposed this proposal. In this contrasting milieu, this paper is aimed at examining how the TRIPS has become a barrier for developing countries' development and distribution of vaccines/technology; secondly, how India strategizes its role in the WTO in pursuant of its global health diplomacy? We conclude that the IPRs regime should not become a barrier to the accessibility/affordability of essential drugs and vaccines. To ensure access, India needs to get more engaged in GHD with all the involved global stakeholders to get strong support for their joint proposal. The developed countries that rejected/resisted the proposal can rethink their full support.
引用
收藏
页数:8
相关论文
共 50 条
[1]  
Abbott F. M, 2020, RES PAPER, V1, P116
[2]  
Albeck-Ripka, 2021, ISRAEL S KOREA AGREE
[3]  
[Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1
[4]  
[Anonymous], 2000, Selected provisions of the WTO Agreements apply with a delay to developing countries. The Customs Valuation Agreement, the TRIMs Agreement, most provisions of the TRIPS Agreement, and some provisions of other agreements applied to India as
[5]  
[Anonymous], 2008, Understanding the WTO, V4th
[6]  
[Anonymous], 2020, Briefing Document
[7]  
Arvind D, 2020, INVENTION INTELLIGEN, V55
[8]  
Barton JH., 2002, Integrating Intellectual Property Rights and Development Policy: Report of the Commission on Intellectual Property Rights
[9]  
Bill C, 9 ACT AMEND PATENT A
[10]  
Brooke S., 2006, VACCINES REGULATORY